Abstract 350P
Background
Immune checkpoint inhibitors (ICI) have demonstrated improvement in overall survival across a range of tumor types. However, ICI therapy is associated with severe immune related adverse events (irAEs) including inflammatory arthritis. Here, we report our experience for rheumatological irAEs in patients with and without pre-existing auto-immune disease (AID).
Methods
Data was collected retrospectively for 15 patients identified as having rheumatological irAEs secondary to ICI therapy in our center between 2015-2019. We identified three patients with pre-existing AID.
Results
The mean age of the cohort was 66 years.The commonest tumour types were melanoma (73%) and NSCLC (27%). In the group without AID, (n=12), 7 patients developed inflammatory arthritis (IA). Two patients with PMR like syndrome depicted typical clinical phenotypes supported by raised inflammatory markers. The SICCA syndrome patient had biopsy proven lichenoid drug eruption and feature of xerostomia. One patient had synovial aspiration proved OA exacerbation treated with intra-articular corticosteroid injection, ceasing ICI. One patient developed grade 3 immune mediated myositis 12 days after commencing nivolumab. Muscle biopsy showed active inflammatory myopathy and lymphocytic vasculitis. Median time to any rheumatologic irAEs was 9.8 weeks. Treatment was withheld temporarily in patient and it was stopped permanently in 2 patients. All patients had high doses of glucocorticoids that led to significant, moderate and minimal improvement in 2, 8 and 2 patients, respectively. Additionally, 3 patients needed other disease modifying anti-rheumatoid drugs (DMARDs). In cohort with pre-existing AID (n=3), only patient with rheumatoid arthritis (RA), had flare of RA after 7 weeks of initiating ICI therapy. ICI therapy was withheld and had resolution of symptoms with steroids.
Conclusions
Rheumatic irAEs are serious and less understood adverse events secondary to ICI therapy requiring steroids and additional immunosuppressive therapy. Future studies should aim at defining the type of rheumatologic irAEs experienced in trials patients and response to steroids +/- DMARDs. A mutli-disciplinary approach is recommended.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Dr. Azim Khan.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
133P - Which patient subgroup needs more attention in early treatment failure? A matched cohort study of treatment failure patterns in locally advanced gastric cancer
Presenter: Dong Wu
Session: e-Poster Display Session
134P - Effect of preoperative tumour under-staging on the long-term survival of patients undergoing radical gastrectomy for gastric cancer
Presenter: Mi Lin
Session: e-Poster Display Session
135P - Significance of lymphatic invasion in the indication for additional gastrectomy after endoscopic treatment
Presenter: Hirohito Fujikawa
Session: e-Poster Display Session
136P - Modified ypTNM staging classification for gastric cancer after neoadjuvant therapy: A multi-institutional study
Presenter: Wen-Wu Qiu
Session: e-Poster Display Session
137P - Clinical utility of circulating tumour DNA (ctDNA) in resectable gastric cancer (GC)
Presenter: Mikhail Fedyanin
Session: e-Poster Display Session
138P - Prognostic importance of dynamic changes in systemic inflammatory markers for patients with gastric cancer
Presenter: Ying-Qi Huang
Session: e-Poster Display Session
139P - An intraoperative model for predicting survival and deciding therapeutic schedules: A comprehensive analysis of peritoneal metastasis in patients with advanced gastric cancer
Presenter: Zhi-Yu Liu
Session: e-Poster Display Session
140P - Preoperative and postoperative C-reactive protein levels predict recurrence and chemotherapy benefit in gastric cancer
Presenter: Li-Li Shen
Session: e-Poster Display Session
141P - Low expression of CDK5RAP3 and UFM1 indicates poor prognosis in patients with gastric cancer
Presenter: Ning-Zi Lian
Session: e-Poster Display Session
142P - Prognostic analysis of patients with intra-abdominal infectious complications after laparoscopy and open radical gastrectomy for gastric cancer: A propensity score-matching analysis
Presenter: Si-Jin Que
Session: e-Poster Display Session